Anti-proliferative effects of the novel squamosamide derivative (FLZ) on HepG2 human hepatoma cells by regulating the cell cycle-related proteins are associated with decreased Ca(2+)/ROS levels

• Published in: Chemico-biological interactions Vol. 193; no. 3; p. 246
• Main Authors: Qin, Yong, Pan, Xiang, Tang, Tian-Tian, Zhou, Liang, Gong, Xing-Guo
• Format: Journal Article
• Language: English
• Published: Ireland 30.09.2011
• Subjects: Acrylamides - chemistry; Acrylamides - pharmacology; Acrylamides - therapeutic use; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Apoptosis - drug effects; Caffeic Acids - chemistry; Caffeic Acids - pharmacology; Caffeic Acids - therapeutic use; Calcium - metabolism; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - metabolism; Cell Cycle Proteins - metabolism; Cell Proliferation - drug effects; Cyclin D1 - metabolism; Cyclin E - metabolism; Cyclin-Dependent Kinase 2 - metabolism; Cyclin-Dependent Kinase Inhibitor p27 - metabolism; G1 Phase; Glutathione - metabolism; Hep G2 Cells; Humans; Liver Neoplasms - drug therapy; Liver Neoplasms - metabolism; Phosphorylation; Proto-Oncogene Proteins c-akt - metabolism; Reactive Oxygen Species - metabolism; Retinoblastoma Protein - metabolism

FLZ is a synthetic novel squamosamide derivative and has previously been proved to be a potential drug for Parkinson's disease and Alzheimer's disease. FLZ has strong antioxidant activity, which implies that FLZ could eliminate excessive intracellular reactive oxygen species (ROS) in tumor...